Potent, long-acting, orally-active bradykinin antagonists for a wide range of applications

Immunopharmacology

Volumn 36, Issue 2-3, 1997, Pages 167-172

  Stewart, John M ^a   Gera, Lajos ^a   Chan, Daniel C ^a   Whalley, Eric T ^b   Hanson, Wendy L ^b   Zuzack, John S ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Cortech ^*  (United States)

Author keywords

Blood pressure; Bradykinin; Bradykinin antagonists; Bradykinin receptors; Cancer; Growth factors; Lung; Orally active; Peptides

Indexed keywords

[[4 [2 [[BIS(CYCLOHEXYLAMINO)METHYLENE]AMINO] 3 (2 NAPHTHYL)PROPIONAMIDO]PHENYL]METHYL]TRIBUTYLPHOSPHONIUM CHLORIDE; B 9430; B 9562; B 9870; BRADYKININ; BRADYKININ ANTAGONIST; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; BRADYKININ RECEPTOR; DELTIBANT; GROWTH FACTOR; ICATIBANT; KALLIKREIN; LYSYLLYSYLARGINYLPROLYL(4 HYDROXYPROLYL)GLYCYL 2 (2,3 DIHYDRO 1H INDEN 2 YL)GLYCYLSERYL 2 (2,3 DIHYDRO 1H INDEN 2 YL)GLYCYLOCTAHYDRO 1H INDOLE 2 CARBOXYLIC ACID; UNCLASSIFIED DRUG;

BLOOD PRESSURE; CARBOXY TERMINAL SEQUENCE; CONFERENCE PAPER; INFLAMMATION; LIGAND BINDING; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN CONFORMATION; SEPTIC SHOCK;

BRADYKININ; CARCINOMA, SMALL CELL; HUMANS; INFLAMMATION; LUNG NEOPLASMS; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2; RECEPTORS, BRADYKININ; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030748582     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(97)00017-9     Document Type: Conference Paper

References (40)

1. Akbary, A.M., Wirth, K.J., Schölkens, B.A., 1996. Efficacy and tolerability of Icatibant (HOE-140) in patients with moderately severe chronic bronchial asthma. Immunopharmacology 33, 238-242.
2. Austin, C.E., Foreman, J.C., Scadding, G.K., 1994. Reduction by HOE-140, the B2 kinin receptor antagonist, of antigen-induced nasal blockage. Br. J. Pharmacol. 111, 969-971.
3. Bhoola, K.D., Figueroa, C.D., Worthy, K., 1992. Bioregulation of kinins: Kallikreins, kininogens and kininases. Pharmacol. Rev. 44, 1-80.
4. Bunn, P.A., Chan, D., Stewart, J., Gera, L., Tolley, R., Jewett, P., Tagawa, M., Alford, C., Mochizuki, T., Yanaihara, N., 1994. Effects of neuropeptide analogues on calcium flux and proliferation in lung cancer cell lines. Cancer Res. 54, 3602-3610.
5. Burch, R.M. (Ed.), 1991. Bradykinin Antagonists. Dekker, New York.
6. Burch, R.M., Kyle, D.J., Stormann, T.M., 1992. Molecular Biology and Pharmacology of Bradykinin Receptors. RG Landes Co., Austin, Texas.
7. Burkard, M., Zuzack, J.S., Jones, S., Francis, M., Whalley, E.T., Stewart, J.M., Gera, L., 1996. Comparative profile of novel potent bradykinin antagonists at human B1 and B2 receptors. Immunopharmacology 33, 186-190.
8. Cann, J.R., Vavrek, R.J., Stewart, J.M., Mueller, D.D., 1990. Conformational aspects of the interaction of bradykinin and related peptides with sodium dodecyl sulfate. J. Am. Chem. Soc. 112, 1357-1364.
9. Chan, D., Gera, L., Helfrich, B., Helm, K., Stewart, J., Whalley, E., Bunn, P., 1996. Novel bradykinin antagonist dimers for the treatment of human lung cancers. Immunopharmacology 33, 201-204.
10. Cheronis, J.C., Whalley, E.T., Nguyen, K.T., Eubanks, S.R., Allen, L.G., Duggan, M.J., Loy, S.D., Bonham, K.A., Blodgett, J.K., 1992. A new class of bradykinin antagonists: Synthesis and in vitro activity of bissuccinimidoalkane peptide dimers. J. Med. Chem. 35, 1563-1572.
11. 2 antagonist activity. J. Med. Chem. 37, 348-355.
12. Freedman, R., Jarnagin, K., 1992. Cloning of a B2 bradykinin receptor: Examination of the bradykinin binding site by site directed mutagenesis. Agents Actions 38/SI, 487-496.
13. Gera, L., Stewart, J.M., Whalley, E., Burkard, M., Zuzack, J.S., 1996. New bradykinin antagonists having very high potency at B1 receptors. Immunopharmacology 33, 183-185.
14. Hanson, W.L., McCullough, R.G., Selig, W.M., Weiczorek, M., Ross, S., Whalley, E.T., Stewart, J.M., Gera, L., 1996. In vivo pharmacological profile of novel, potent, stable BK antagonists at B1 and B2 receptors. Immunopharmacology 33, 191-193.
15. Hock, F.J., Wirth, K., Albus, U., Linz, W., Gerhards, H.J., Wiemer, G., Henke, St., Breipohl, G., König, W., Schölkens, B.A., 1991. HOE-140, a new, potent and long acting bradykinin antagonist: In vitro studies. Br. J. Pharmacol. 102, 769-773.
16. Inamura, N., Asano, M., Kayakiri, H., Hatori, C., Oku, T., Nakahara, K., 1997. Characterization of FR173657, a novel, non-peptide BK2 antagonist, in vitro and in vivo. Can. J. Physiol. Pharmacol., in press.
17. Kyle, D.J., Martin, J.A., Burch, R.M., Carter, J.P., Lu, S., Meeker, S., Prosser, J.C., Sullivan, J.P., Togo, J., Noronha-Blob, L., Sinsko, J.A., Walters, R.F., Whaley, L.W., Hiner, R.N., 1991. Probing the bradykinin receptor: Mapping the geometric topography using ethers of hydroxyproline in novel peptides. J. Med. Chem. 34, 2649-2653.
18. Kyle, D.J., Blake, P.R., Smithwick, D., Green, L.M., Martin, J.A., Sinsko, J.A., Summers, M.F., 1993. NMR and computational evidence that high affinity bradykinin receptor antagonists adopt C-terminal b-turns. J. Med. Chem. 36, 1450-1460.
19. Kyle, D.J., Chakravarty, S., Sinsko, J.A., Stormann, T.M., 1994. A proposed model of bradykinin bound to the rat B2 receptor and its utility for drug design. J. Med. Chem. 37, 1347-1354.
20. Liu, X., Stewart, J.M., Gera, L., Kotovych, G., 1993. Proton magnetic resonance studies of bradykinin antagonists. Biopolymers 33, 1237-1247.
21. Maeda, H., Akaike, T., Sakata, Y., Maruo, K., 1993. Role of bradykinin in microbial infection: Enhancement of septicemia by microbial proteases and kinins. In: Cheronis, J.C., Repine, J.E. (Eds.), Proteases, Protease Inhibitors and Protease-derived Peptides. Birkhauser Verlag, Basel, pp. 159-165.
22. Maeda, H., Akaike, J.W., Noguchi, Y., Sakata, Y., 1996. Bradykinin and nitric oxide in infectious disease and cancer. Immunopharmacology 33, 222-230.
23. Marceau, F., 1995. Kinin B1 receptors: A review. Immunopharmacology 30, 1-26.
24. Nardone, J., Hogan, P.G., 1994. Delineation of a region in the B2 bradykinin receptor that is essential for high-affinity binding. Proc. Nat. Acad. Sci. USA 91, 4417-4421.
25. Regoli, D., Barabe, J., Park, W.K., 1977. Receptors for bradykinin in rabbit aorta. Can. J. Physiol. Pharmacol. 55, 855-867.
26. Regoli, D., Drapeau, G., Rovero, P., Dion, S., Rhaleb, N.-E., Barabe, J., D'Orleans-Juste, P., Ward, P., 1986. Conversion of kinins and their antagonists into B1 receptor activators and blockers in isolated vessels. Eur. J. Pharmacol. 127, 219-224.
27. Rodell, T.C., 1996. The kallikrein/kinin system and kinin antagonists in trauma. Immunopharmacology 33, 279-283.
28. 2 receptor. J. Med. Chem. 36, 2583-2584.
29. Sejbal, J., Cann, J.R., Stewart, J.M., Gera, L., Kotovych, G., 1996. An NMR, CD, molecular dynamics and fluorimetric study of the conformation of the bradykinin antagonist B-9340 in water and in aqueous micellar solutions. J. Med. Chem. 39, 1281-1292.
30. Stewart, J.M., 1989. Roles for kinins in inflammation. In: Henson, P.M. and Murphy, R.C. (Eds.), Mediators of the Inflammatory Process. Elsevier, Amsterdam, pp. 189-217.
31. Stewart, J.M., Gera, L., 1996. A new class of bradykinin antagonists containing indanylglycine. Immunopharmacology 33, 174-177.
32. Stewart, J.M., Vavrek, R.J., 1991. Chemistry of peptide B2 bradykinin antagonists. In: Burch, R.M. (Ed.), Bradykinin Antagonists. Pergamon, Oxford, pp. 51-96.
33. Stewart, J.M., Gera, L., Srivastava, V., 1993. Bradykinin antagonists without aromatic amino acids. In: Schneider, C.H., Eberle, E. (Eds.), Peptides 1992. ESCOM, Leiden, pp. 691-692.
34. Stewart, J.M., Gera, L., Hanson, W., Zuzack, J.S., Burkard, M., McCullough, R., Whalley, E.T., 1996. A new generation of bradykinin antagonists. Immunopharmacology 33, 51-60.
35. Stewart, J.M., Gera, L., Chan, D.C., Whalley, E.T., Hanson, W.L., Zuzack, J.S., 1997. Potent, long-acting bradykinin antagonists for a wide range of applications. Can. J. Physiol. Pharmacol., in press.
36. 7 substituted peptide bradykinin antagonists are not substrates for kininase II. Peptides 10, 109-112.
37. Vavrek, R.J., Stewart, J.M., 1985. Competitive antagonists of bradykinin. Peptides 6, 161-164.
38. Whalley, E.T., Solomon, J.A., Madafferi, D.M., Bonham, K.A., Cheronis, J.C., 1992. CP-0127, a novel potent bradykinin antagonist, increases survival in rat and rabbit models of endotoxin shock. Agents Actions 38/SI, 413-420.
39. Whalley, E.T., Hanson, W.L., Stewart, J.M., Gera, L., 1997. Oral activity of peptide bradykinin antagonists. Can. J. Physiol. Pharmacol., in press.
40. Wirth, K., Hock, F.J., Albus, U., Linz, W., Alpermann, H.G., Anagnostopoulos, H., Henke, S., Breipohl, G., Konig, W., Knolle, J., Scholkens, B.A., 1991. HOE 140, a new potent and long acting bradykinin antagonist: In vivo studies. Br. J. Pharmacol. 102, 774-777.